Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Nagata Y, Kageyama S, Ishikawa T, Kokura S, Okayama T, Abe T, Murakami M, Otsuka K, Ariyoshi T, Kojima T, Taniguchi K, Kobayashi S, Shimada H, Yajima S, Suzuki T, Hirano S, Tsuchikawa T, Shichinohe T, Ueda S, Kanetaka K, Yoneda A, Wada H, Doki Y, Yamaue H, Katsuda M, Ohi M, Yasuda H, Kondo K, Kataoka M, Kodera Y, Koike M, Shiraishi T, Miyahara Y, Goshima N, Fukuda E, Yamaguchi K, Sato E, Ikeda H, Yamada T, Osako M, Hirai K, Miyamoto H, Watanabe T, Shiku H. Nagata Y, et al. Among authors: sato e. Cancer Immunol Immunother. 2022 Nov;71(11):2743-2755. doi: 10.1007/s00262-022-03194-5. Epub 2022 Apr 16. Cancer Immunol Immunother. 2022. PMID: 35429246 Free PMC article. Clinical Trial.
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K. Tsuji K, et al. Among authors: sato e. Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1. Cancer Immunol Immunother. 2008. PMID: 18311489 Free PMC article.
Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S. Aoki M, et al. Among authors: sato e. Vaccine. 2009 Nov 16;27(49):6854-61. doi: 10.1016/j.vaccine.2009.09.018. Epub 2009 Sep 15. Vaccine. 2009. PMID: 19761832 Clinical Trial.
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
Kageyama S, Wada H, Muro K, Niwa Y, Ueda S, Miyata H, Takiguchi S, Sugino SH, Miyahara Y, Ikeda H, Imai N, Sato E, Yamada T, Osako M, Ohnishi M, Harada N, Hishida T, Doki Y, Shiku H. Kageyama S, et al. Among authors: sato e. J Transl Med. 2013 Oct 5;11:246. doi: 10.1186/1479-5876-11-246. J Transl Med. 2013. PMID: 24093426 Free PMC article. Clinical Trial.
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
Ishihara M, Tono Y, Miyahara Y, Muraoka D, Harada N, Kageyama S, Sasaki T, Hori Y, Soga N, Uchida K, Shiraishi T, Sato E, Kanda H, Mizuno T, Webster GA, Ikeda H, Katayama N, Sugimura Y, Shiku H. Ishihara M, et al. Among authors: sato e. Cancer Immunol Immunother. 2020 Apr;69(4):663-675. doi: 10.1007/s00262-020-02483-1. Epub 2020 Jan 24. Cancer Immunol Immunother. 2020. PMID: 31980914 Free PMC article. Clinical Trial.
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Ishikawa T, Kageyama S, Miyahara Y, Okayama T, Kokura S, Wang L, Sato E, Yagita H, Itoh Y, Shiku H. Ishikawa T, et al. Among authors: sato e. Cancer Immunol Immunother. 2021 Nov;70(11):3081-3091. doi: 10.1007/s00262-021-02892-w. Epub 2021 Mar 22. Cancer Immunol Immunother. 2021. PMID: 33751208 Free PMC article. Clinical Trial.
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: sato e. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.
Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. Uenaka A, et al. Among authors: sato e, sato s. Cancer Immun. 2007 Apr 19;7:9. Cancer Immun. 2007. PMID: 17441676 Free PMC article. Clinical Trial.
1,960 results